IP Library Granted Patent US 9,370,535
Granted Patent B2
US 9,370,535 · App. 13/467,147 · Granted Jun 21, 2016

Method for treatment of advanced solid tumors

Inventors: Tillmann Taube (Biberach an der Riss, DE); Gerd Michael Munzert (Ulm, DE); Dorothea Rudolph (Vienna, AT)
Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
A61K33/24A61K31/282A61K31/519A61K31/555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,370,535
App. No.
13/467,147
Granted
Jun 21, 2016
Kind
B2
Abstract

The present invention relates to the use of Volasertib or a salt thereof or a hydrate thereof in combination with Cisplatin or Carboplatin or a salt thereof or a hydrate thereof for treating patients suffering from advanced and/or metastatic solid tumors.

Claims (14)

1. A method of treating advanced and/or metastatic solid tumours, comprising administering 300 to 500 mg Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof to a patient at one day during a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle in combination with

b) 50 to 100 mg/m 2 BSA of Cisplatin at one day within the same treatment cycle or Carboplatin at a dose targeting AUC=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle, to a patient suffering from advanced or metastatic solid tumours.

2. The method according to claim 1 , comprising administering a dosage schedule (I) comprising or consisting of

a) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and

b) 50 to 100 mg/m2 BSA of Cisplatin at one day within the same treatment cycle, to a patient suffering from advanced or metastatic solid tumours.

3. The method according to claim 1 , comprising administering a dosage schedule (I) comprising or consisting of

a) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and

b) Carboplatin at a dose targeting AUC=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle,

to a patient suffering from advanced or metastatic solid tumours.

4. The method according to claim 2 or 3 , wherein the treatment cycle is 14, 21 or 28 days.

5. The method according to claim 2 , wherein Volasertib and Cisplatin are administered at the same day.

6. The method according to claim 3 , wherein Volasertib and Carboplatin are administered at the same day.

7. The method according to claim 5 , wherein Volasertib and Cisplatin are administered at the same time.

8. The method according to claim 6 , wherein Volasertib and Carboplatin are administered at the same time.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 16, 2020
From: BOEHRINGER INGELHEIM PHARMA GMBH,
To: ONCOHEROES BIOSCIENCES INC.,
Reel/Frame 052953/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2012
From: TAUBE, TILLMANN; MUNZERT, GERD MICHAEL; RUDOLPH, DOROTHEA
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 028526/0390 →
Priority Claims (1)
EP 11166365 · May 17, 2011 · regional
Continuity (1)
Related Publication 20130122111A1 · May 16, 2013